BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) will announce its fourth quarter and full year 2020 financial results on February 25, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. The call can be accessed by dialing 877-303-8027 for domestic and 760-536-5165 for international callers. Additionally, BioCryst's lead product, ORLADEYO™, is under regulatory review in the European Union, while ongoing developments include treatments for rare diseases and viral infections.

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 6779206. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 6779206.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investors:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals report its Q4 and full year 2020 financial results?

BioCryst Pharmaceuticals will report its Q4 and full year 2020 financial results on February 25, 2021.

What time is the BioCryst Pharmaceuticals conference call?

The BioCryst Pharmaceuticals conference call will take place at 8:30 a.m. ET on February 25, 2021.

How can I access the BioCryst Pharmaceuticals conference call?

You can access the BioCryst Pharmaceuticals conference call by calling 877-303-8027 for domestic callers or 760-536-5165 for international callers, using conference ID # 6779206.

What is the status of ORLADEYO™ from BioCryst Pharmaceuticals?

ORLADEYO™ is approved in the U.S. and Japan for HAE prevention and is under regulatory review in the European Union.